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Polyunsaturatedfattyacid(PUFA)useinpregnancyhasbeenpromotedasbeneﬁcialforvisualandneurobehaviouraldevelopment
in the fetus. However, no systematic review of the randomized trials has been conducted. The objective of this review was to evalu-
ate potential advantages of this regiment by reviewing all randomized trials in pregnancy. Methods.S y s t e m a t i cr e v i e wo fr a n d o m -
ized controlled studies comparing cognitive and visual achievements among infants whose mothers were treated and untreated
with PUFA during gestation. Results. Nine studies met the inclusion criteria, three focusing on visual and six on neurobehavioural
development. Due to diﬀering outcome measurements in the infants, the studies could not be combined into a formal meta-
analysis. Synthesizing the existing data, for both visual and neurobehavioural development, most studies could not show sustained
beneﬁts to infant cognition or visual development. Conclusion. At the present time a recommendation to change practice and
supplement all expecting mothers with PUFA to improve oﬀspring vision or neurobehavioural function is not supported by
existing evidence.
1.Introduction
Polyunsaturatedfattyacids (PUFAs)of the ω-3 and ω-6 fam-
ilies cannot be synthesized by the human body [1], making
the parent fatty acids of these families—alpha-linolenic acid
(ALA) and linoleic acid (LA)—essential fatty acids that must
be obtained from the diet [2]. ALA is converted into eicos-
apentaenoic acid (EPA) and then to docosahexaenoic acid
(DHA), a critical component of cell membranes especially
in the brain and retina. LA is converted into arachidonic acid
(AA), a membrane component and a precursor to signaling
molecules [2]. The ratio of the ω-3 to ω-6 families of PUFAs
is critical because both families are metabolized by the same
enzymes, and increasing the amount of ω-3 fatty acids (FAs)
in the diet, for example, may decrease the availability of the
ω-6 products. Therefore, there is a potential risk of reducing
AA levels in the fetus with maternal supplementation of ω-3
FAs [1].
Because the PUFAs required by the fetus are supplied by
preferentialplacentaltransferofpreformedlong-chainPUFA
(LC-PUFA) rather than the precursors ALA and LA, it has
been proposed that additional maternal supply of DHA and
AAduringpregnancymayimproveearlycognitiveandvisual
development [3]. The limited available data on LC-PUFA in
the developing human brain indicates that fetal accumula-
tion of LC-PUFA is slow in the earlier weeks of gestation and
rapidly increases in the third trimester [4].
Among the ω-3 FAs subtypes, DHA is the only one that
accumulates to an appreciable extent in the developing brain2 Obstetrics and Gynecology International
and eye [5]. DHA is actively and preferentially transferred to
the fetus by speciﬁc fatty acid placental transfer and mem-
brane binding proteins. Of all cells, the highest content of
DHA is found in retinal photoreceptors, the cells responsible
for phototransduction [6]. As well, the visual cortex of the
brain has high levels of DHA. Brain and visual development
is most sensitive to malnutrition in the third trimester and in
the ﬁrst 18 weeks of postnatal life. In Rhesus monkeys and
rats fed diets limited in LCPUFA during pregnancy, there are
reduced levels of PUFAs in pups in both the retina and the
visualcortex[7–9].PregnantRhesusmonkeysandtheirpups
fed diets low in n-3 fatty acids exhibit below normal visual
acuity scores at 4–12 weeks compared to mother and infant
monkey pairs fed diets with “ample” n-3 fatty acids [9].
In animal studies, severe restriction of ω-3 fatty acids re-
sultsinlowerconcentrationsofDHAinthebrainandpoorer
cognitive and behavioural capacities [10]. Several human
studies have suggested that maternal diet rich in seafood cor-
relates with higher scores on tests of cognitive function. Ob-
servational studies have suggested that prenatal AA status
correlates positively with neurodevelopmental outcome dur-
ing early infancy, but not at older ages [4].
In Health Canada “Prenatal Nutrition Guidelines for
HealthProfessionals,”womenareadvisedtoconsumeatleast
150gofcookedﬁshweekly,preferablythosewithlowerlevels
of contaminants such as methyl mercury and polychlori-
nated biphenyls (PCBs), suggesting that ﬁsh intake during
pregnancy may be linked to better infant and child develop-
ment [11]. With respect to LC-PUFA supplementation, it is
advised that ﬁsh oil supplements should not be considered
equivalent to eating ﬁsh, and though they provide ω-3 fatty
acids, there is insuﬃcient evidence to draw conclusions on
the eﬀects of ﬁsh oil supplementation on infant development
[12]. Observational studies correlating PUFA with fetal de-
velopment suﬀer from numerous confounders that may af-
fect outcome, such as socioeconomic status, maternal educa-
tion, and other nutrients status.
The objective of this systemic review was to evaluate the
potential eﬀects of interventional supplementation of ω-3
FAsduringthepregnancyperiodonlyoninfantneurobehav-
ioral and visual development, without the potential eﬀects of
breastfeeding or dietary supplementation.
2.MaterialandMethods
2.1. Inclusion and Exclusion Criteria. Studies included in this
review were randomized control trials (RCTs) comparing
LC-PUFA supplementation with placebo or no supplemen-
tation in pregnant women. Trials that used supplementation
only during breastfeeding and/or infant dietary supplemen-
tation were excluded. In contrast, trials that started in preg-
nancy but continued during breastfeeding were included.
Trials reporting only biochemical outcomes or using animals
were not included and only original research articles were
considered. Trials in which precursors of essential FAs (ALA
and LA) were used in intervention group were not included
because the preferential placental transfer for LC-PUFAs
precursorsisfarlesseﬀective.Abstractsforwhichapublished
full paper could not be located were excluded for this review.
To ensure a high quality of evidence, we restricted the re-
view to RCTs with Jadad scores of 3 or greater on the 5-point
scale [13].
2.2. Search Strategy. We completed a computerized literature
search of MEDLINE (1950–June 2010), EMBASE (2010), the
Cumulative Index to Nursing and Allied Health (CINALH)
(from inception to June 2010), and the Cochrane Library
(2010). We supplemented this search by investigating rele-
vant references from published reviews [2–4, 14, 15]. There
was no limit on the language of publication.
Search terms used were “omega or n-6 or n-3 or eicos-
apentaenoic acid or EPA or docosahexaenoic acid or DHA
or arachidonic acid or LC-PUFA or long-chain fatty acid or
essential fatty acid or ﬁsh oil or fatty acid” and “supplemen-
tation” and “pregnancy or maternal.”
2.3. Methods of Review
Trial Selection. Two researchers independently applied the
inclusion criteria to each potential relevant trial and differ-
ences with regards to their eligibility were resolved by con-
sensus.
2.4. Quality Assessment. Two researchers independently as-
sessedthequalityofthestudiesthatmettheinclusioncriteria
using the Jadad method [13], and articles included had to
score between 3 and 5 on the 5-point scale.
3. Results
All 9 identiﬁed randomized trials met our inclusion criteria,
and all of them achieved at least 3 on the Jadad score (Figure
1).Threetrialswerefocusedonretinaldevelopment[16–18]
while six studied neurodevelopment [16, 19–23]. Though
trialswithallLC-PUFA(ω-3andω-6)supplementationwere
considered for this review, none of the trials used ω-6 in the
intervention group. The characteristics of the included trials
are summarized in Table 1.T h ed u r a t i o n ,s o u r c e s ,a n d
amounts of ω-3 LC-PUFA, DHA, and EPA supplied varied
among trials. The doses ranged from 2 × 100mg DHA/week
[17, 18] to 1.1g EPA, 2.2g DHA/day, which were used in the
studybyDunstanetal.[19].Thetrialsdiﬀeredinthestarting
point of intervention, ranging from the 15th [17, 18] to the
25th weeks of gestation [23]. All trials ended supplementa-
tion at delivery, with the exception of the studies by Helland
et al. [20–22], which continued supplementation until 3
months after delivery. Because these studies did not change
the practice of breastfeeding between control and treatment
groups, we still included them in our review. Because the
methods of measuring visual and neurodevelopmental out-
comes varied widely among studies, the combination of the
results into a formal meta-analysis was deemed inappropri-
ate.
3.1. Eﬀectiveness of PUFA for Visual Development. To allow
readers who are not specialists in measuring visual develop-
mentto followthe results,the description of the study resultsObstetrics and Gynecology International 3
903 articles found during
search (completed June 30,
2010)  
63 titles screened for
 inclusion 
11 articles retrieved for full
analysis 
8 articles included in
systematic review (including
9 studies 3 visual and 6
neurocognitive)    
840 articles rejected after
review of article type for
reviews, letters, case
reports and so on   
Figure 1: Search strategy ﬂow chart.
is preceded by description of the methods used by the diﬀer-
ent groups. There are various ways to assess vision in hu-
mans; however, not all of these methods can be used as
diagnostic tools in children, let alone in infants. Both visual
function (the ability to see) and visual acuity (a quantiﬁable
measure of vision function) can be tested. There are several
aspects of visual acuity (the spatial limit of visual discrimina-
tion): detection, resolution, identiﬁcation, and hyperacuity.
A commonly used test, Teller Acuity Cards [25], tests resolu-
tion, or the smallest angular separation between two objects
side by side [26].
Visual function may also be assessed using objective elec-
trophysiological measures such as the visual evoked poten-
tials(VEPs)(steadystateandtransient).Retinalfunctioncan
be assessed using the electroretinogram (ERG). The Inter-
national Society of the Clinical Electrophysiology of Vision
(ISCEV) provides standards for both VEP and ERG testing
[27, 28]. VEPs are recorded with electrodes placed on the
back of the scalp to measure the responses generated by the
visual cortex in response to a change in visual stimulus. Re-
sponses to this test indicate the function of the visual path-
way: retina, optic nerve, and brain (speciﬁcally the occipital
cortex) and are dependent on unobstructed ocular media
such as the cornea and lens. When used to assess visual func-
tion, the VEP does not localize where in the visual pathway
damage exists. ERGs are measured using electrodes placed
on the cornea of the eye and forehead. Subjects are presented
with ﬂashes of light of diﬀerent intensities and the resulting
responses generate characteristic outputs. The positive and
negative peaks of diﬀerent outputs are known to originate in
speciﬁc areas of the retina which localize damage to a speciﬁc
layer of the retina. Both VEPs and ERGs can be described in
terms of amplitude and implicit time or latency of the res-
ponse.
Judge et al. conducted a longitudinal, double-blinded
RCTofthirtynonsmoking womensupplementedwitheither
DHA-rich (mean = 2 1 4 m g / d )c e r e a lb a r so rp l a c e b ob a r s
starting at 24 weeks of gestation [24]. Infants were as-
sessed at 4 and 6 months of age by Teller Acuity Cards Pro-
cedure (ACP) which is a type of preferential looking test for
resolution. Thistechniqueassumesthatchildrenwouldrath-
er look at a pattern than a blank stimulus [29]. It consists of
a series of gray cards with one circle with a black and white
grating (of diﬀerent frequencies) and another card of equal
luminance to the grating. An observer must identify that the
child has preferentially looked at the grated stimulus (but are
themselves blinded to which side the grated stimulus is on).
Thetestisrepeated,switchingthesideofthegratedstimulus,
untiltheobserverfeelstheycanreliablydecipherwhetherthe
child is in fact preferentially looking at the grated card. That
grating frequency, referred to as a spatial frequency, is then
said to be above the child’s acuity threshold. After adjusting
for potential confounding factors, including infant feeding
type, there was a signiﬁcant diﬀerence in visual acuity be-
tween groups at 4 months, but not at 6 months postnatally.
Both supplemented and nonsupplemented groups showed4 Obstetrics and Gynecology International
Table 1: Description of included studies.
Study (year) Jadad
score
Treatments—maternal diet
supplementation Outcome N Test results
Treatments and outcomes for studies considered—retinal development
Malcolm [17]3
Controls (C): 2 placebo capsules
(323mg sunﬂower oil)/day
Treatment: 2 ﬁsh oil capsules (blended
ﬁsh oil, Marinol D40: 100mg DHA)/day
From wk 15 of pregnancy until delivery
Age: 50 and 66wks
after conceptional
age—visual evoked
potential (transient
VEP P100 peak
latencies (ms))
DHA: n = 31
C: n = 29
No eﬀect of group at any
time
Judge [16, 24]4
Controls: 3,5, or 7 placebo cereal bars
(corn oil)/wk
Treatment: 3, 5, or 7 cereal bars (300mg
DHA)/wk (average was 5 bars/wk:
214mg/d of DHA)
From wk 24 of pregnancy until delivery
Age: 4 and 6mo
Teller Acuity Cards
DHA: n = 16
C: n = 14
4m o n t h s
DHA: 3.7 ± 1.3 c/d
C: 3.2 ± 1.3 c/d P = 0.018
No diﬀerence at 6 months
Malcolm [18]4
Controls: 2 placebo capsules
(sunﬂower oil)/day DHA: n = 31
Treatment: 2 ﬁsh oil capsules (Marinol
D40: 100mg DHA)/day, total 200mg/d
from wk 15 of pregnancy until delivery
Age: within 1wk of
birth Scotopic
electroretinogram
C: n = 29 No eﬀect of group on VEP
maturity
Treatments and outcomes for studies considered—neurodevelopment
Tofail [23]4
Controls: 4 placebo capsules (soybean
oil: total 2.25g LA and 0.27g LNA)/day
Treatment: 4 ﬁsh oil capsules
(total 1.2g DHA and 1.8g EPA)/day
From wk 25 of pregnancy until delivery
Age: 10mo
Bayley Scales of Infant
Development II,
Mental Developmental
Index (MDI)
Psychomotor
Developmental Index
(PDI)
Fish oil
n = 125
Soy oil
n = 124
Mental developmental index:
Fish 102.5 (8.0) Soy 101.5
(7.8)
95% CI of diﬀerence
between means: −0.98, 3.0
Psychomotor developmental
index Fish 101.7 (10.9)
Soy 100.5 (10.1)
95% CI of diﬀerence
between means: −1.3, 3.8
Judge [16, 24]3
Controls:3 ,5 ,o r7p l a c e b oc e r e a lb a r s
(corn oil)/wk
Treatment: 3,5, or 7 cereal bars (300mg
DHA)/wk (overall average of 214mg/d
of DHA)
From wk 24 of pregnancy until delivery
Age: 9mo
Infant planning test
(IPT)
Fagan test of infant
intelligence (FTII)
IPT
DHA: n = 14
C: n = 15
FTII
DHA: n = 15
C: n = 15
Infant planning test
(1) Intention score
DHA = 8 (2.3),
C = 6.7 (3)
P2 = 0.017
(2) Intentional solutions
DHA = 2.5 (1.3),
C = 1.7 (1.5)
P2 = 0.011
Fagan test Scores for 5
diﬀerent variables, no
signiﬁcant diﬀerence in any
Helland [20–22]4
Controls: 10ml corn oil (4747mg LA,
92mg alpha LA)/day
Treatment: 10ml cod liver oil (1183mg
DHA, 803mg EPA)/day
From wk 17–19 of pregnancy until 3
months after delivery
Age: 2nd day and
3moEEG
Age:6moand9mo:
Fagan test
2nd day
EEG
T: n = 66
C: n = 83
3mo
T: n = 61
C: n = 61
Fagan 6mo
T: n = 144
C: n = 118
9mo:
T: n = 130
C: n = 115
EEG: no diﬀerence b/w
groups at both ages. Fagan:
no diﬀerence at either time.Obstetrics and Gynecology International 5
Table 1: Continued.
Study (year) Jadad
score
Treatments—maternal diet
supplementation Outcome N Test results
Helland [20–22]4
Controls:1 0m lc o r no i l
(4747mg LA, 92mg alpha LA)/day
Treatment: 10ml cod liver oil (1183mg
DHA, 803mg EPA)/day From wk 18 of
pregnancy until 3m o n t h safter delivery
Age: 4yrs
Kaufman Assessment
Battery for Children
(K-ABC)
Cod oil:
n = 48
Corn oil:
n = 36
K-ABC mental processing
composite 4 yrs: 106.4 (7.4)
versus 102.3 (11.3) for
control
P = 0.049
Helland [20–22]3
Controls:1 0m lc o r no i l
(4747mg LA, 92mg alpha LA)/day
Treatment: 10ml cod liver oil (1183mg
DHA, 803mg EPA)/day From wk 18 of
pregnancy until 3m o n t h sa f t e rdelivery
Age: 7yrs
Kaufman Assessment
Battery for Children
(K-ABC)
Cod:
n = 82
Corn:
n = 61
K-ABC mental processing
composite—no diﬀerence
Dunstan [19]3
Controls: 4–1g olive oil capsules
(total 2.7g n9 oleic acid)/day
Treatment: 4–1g ﬁsh oil capsules (total
1.1g EPA, 2.2g DHA)/day (3.7g of ω-3
PUFA/d) From wk 20 of pregnancy
until delivery
Age: 2.5yr
Griﬃths Mental
Development Scales
(GMDS)
Peabody picture
vocabulary test IIIA
Child Behavior
checklist 1.5–5y
T: n = 52
C: n = 46
Hand and eye coordination
T( n = 33): 114 (10.2) C
(n = 39): 108 (11.3)
P = 0.008
No signiﬁcant diﬀerence on
other tests
an increase in ACP score over time but the change in score
over time was not signiﬁcantly diﬀerent between the two
groups and the authors suggested that DHA supplementa-
tion aided in visual system maturation [24].
Malcolm et al. conducted a prospective placebo con-
trolled, randomized double-blind trial investigating electror-
etinogram (ERGs) in infants born to 100 woman supple-
mented with 200mg DHA or 200mg sunﬂower oil placebo
from week 15 of pregnancy until birth [17]. This study was
well designed and used the bipolar Burien Allen electrodes
and a Ganzfeld dome, known to elicit repeatable valid re-
sponses [28]. These tests were administered to the children
without sedation which can be problematic based on the
child’s level of cooperation. The authors reported that infant
DHA status, and ERG implicit times, amplitude, and stimu-
lusresponsefunctionsatbirth,didnotdiﬀerbetweengroups
for 60 infants tested within one week of birth [17]. However,
infants in the highest quartile for cord blood DHA had sig-
niﬁcantly higher retinal sensitivity (logσ) as compared with
those in the lowest quartile, and those in the highest quartile
for plasma DHA were born at signiﬁcantly later gestational
age than those in the lower quartile, regardless of maternal
supplementationtype.Theauthorsconcludedthat,although
maternal supplementation had no eﬀect on infant DHA
statusorretinaldevelopment,thoseinfantswithhigherDHA
status had increased retinal sensitivity and longer gestational
age [17].
Malcolm et al. also tested this cohort using VEPs [18].
After supplementation, red blood cell (RBC) DHA concen-
tration and the percentage of total fatty acids (%TFA) in
pregnant women (n = 54) were higher in the ﬁsh oil group
thanintheplacebogroupfrom28wkstodelivery(P<0.05).
As before, DHA supplementation did not signiﬁcantly ele-
vate levels of DHA measured as RBC concentration of %TFA
in umbilical cord blood. Fifty-ﬁve infants tested showed no
signiﬁcant group diﬀerences in mean peak latencies of major
components of ﬂash VEP waveform or in the peak latency of
the P100 component of the pattern-reversal VEP, and no sig-
niﬁcant correlation was detected between ﬂash VEP peak la-
tencies and RBC/plasma DHA levels in cord blood at any
time (birth, 50 weeks after conceptional age (PCA), and
66 weeks PCA). Similarly, no diﬀerences were found in the
threshold check size of the pattern-reversal VEP at 50 or
66 weeks PCA between supplementation groups. Pattern-
reversalVEPmaturity,measuredasshorterpeaklatency,cor-
related at 50 weeks and 66 weeks PCA with cord DHA status,
but not with maternal supplementation group. Here, infants
in the top quartile of RBC DHA status (median −5.46%) did
not diﬀer signiﬁcantly in VEP maturity from those in the
lowest quartile (median −3.45%).
3.2. Neurodevelopment. Six trials met the inclusion criteria,
achieving Jadad scores of at least 3. Of these six trials, three
were published by Helland et al. based on followup of one
RCT [20–22]. Therefore, there was a total of four indepen-
dent RCTs included in this part of the systemic review.
Various methods of measuring neurodevelopment were
used in the six papers accepted for this review, and these will
be described to allow the reader to evaluate the results. The
Bayley Scales of Infant Development Second Edition (BSID-
II) is a standardized test used to assess motor and cognitive
development of children between the ages of zero and three
years. Raw scores are compared with age-based normative
data to determine individual standard scores. The BSID-II
includestwosubscales:thementaldevelopmentindex(MDI)
and psychomotor development index (PDI) [30, 31]. Using
this method, Tofail et al. found no signiﬁcant diﬀerence be-
tween the MDI and PDI scores of 10-month-old children of
mothers supplemented with ﬁsh oil or soy oil during the last
trimesterofpregnancy[23]. This study took place in Bangla-
desh, and 28% of the mothers in the test population suﬀered
from undernutrition. The authors speculated that because
there was attrition of 38% from the original randomized6 Obstetrics and Gynecology International
sampleandtheattrition samplewasatgreaterrisk forneuro-
developmental problems due to clinical diﬃculties during
pregnancy, the lack of treatment eﬀect may be attributed to
the attrition of those that likely would have beneﬁted most
from treatment. In addition, the authors commented on the
lackofvalidationorstandardizationoftheBayley-IIinBang-
ladesh, which may have limited the sensitivity to detect
minor diﬀerences between groups [23].
Judge et al. used the infant planning test and Fagan tests
tocomparetheneurodevelopmentof9-month-oldinfantsof
mothers supplemented with DHA or placebo during preg-
nancy [16]. The Fagan test is used to estimate infants’ recog-
nition memory, as a proxy of intellectual ability, by present-
ing them with novel and familiar facial pictures [32]. Those
children who spend more time ﬁxating on novel stimuli are
given higher scores. This test is thought to represent the
speed with which infants acquire new knowledge and has
been shown to moderately correlate with IQ at 2 years of life
[33].Thistaskassessesasingleaspectofdevelopment,name-
ly, facial (visual) recognition.
Other standardized infant developmental tests (e.g., Bay-
ley Scales of Infant Development, Mullen Scales of Early
Learning) use a variety of tasks to estimate infant IQ and,
based on their assessment of other functions (e.g., motor,
language,and other problem-solvingtasks),may actasa bet-
ter estimate of later cognitive functioning. The infant plan-
ningtestrequiresinfantstoexecuteaseriesofstepstoretrieve
a toy as a measure of their problem solving ability [33–37].
This test, as well as its method for scoring and assessing per-
formance, is unpublished and has no available reliability or
validity information, limiting the interpretation of the ﬁnd-
ings. The women from both study groups were instructed to
c o n s u m e3 ,5 ,o r7c e r e a lb a r s / w kf r o mw e e k2 4t od e l i v e r y .
The average was 5 bars a week, averaging 214mg/d of DHA
consumption. Signiﬁcantly higher problem-solving scores
(i.e., better performance) were associated with maternal
PUFA supplementation as measured by the infant planning
test. However, there was no diﬀerence detected in facial rec-
ognition by the Fagan test. The authors stated that the lack of
signiﬁcant diﬀerences may not be surprising, as the Fagan
test is more sensitive at 4 and 6 months of age [38]. Another
possibility is that PUFA supplementation may not impact
thisspeciﬁcskillofdevelopmentasitisthoughttobeameas-
ure of selective visual attention and facial recognition.
Helland et al.’s three studies examined infants of mothers
supplemented daily with 10mL cod liver oil (1183mg DHA,
803mgEPA) or 10mL corn oil placebo, from wk 18 of preg-
nancy until 3 months after delivery, to measure eﬀects on in-
fant neurodevelopment [20–22]. 242 of the 251 infants were
breastfed at least until 3 months of age, and a subset (n =
130) were started on supplement of cod liver oil (5mL daily
from 4 wks of age). No diﬀerences were found between the
infant diet in the supplemented groups in terms of PUFA
content, and for the sake of the present systematic review we
were interested only in groups that diﬀered with respect to
maternal supplementation. Helland et al. measured neuro-
development at ages day 2 and 3 months using EEG (n =
149) [20], 6 and 9 months using the Fagan test (n = 245)
[21], and 4 years (n = 84) and 7 years (n = 143) using the
Kaufman Assessment Battery for Children (K-ABC) [22],
in which sequential processing, simultaneous processing,
achievement, and nonverbal abilities are scored in a multi-
subtest battery. The raw scores for each category were con-
verted to standard scores according to the American norms
since the Norwegian version has not been standardized.
There were no diﬀerences found in the test scores at any of
the ages [20–22], except at 4 yrs, when children of cod-oil-
supplemented mothers scored higher on the mental process-
ing composite of K-ABC [22].
Dunstan et al. studied the eﬀects of ﬁsh oil (3.7g of ω-3
PUFA/d) supplementation during pregnancy from wk 20 to
delivery on several scales of cognitive assessment of the child
at age 2.5yrs [19]. The Griﬃths Mental Development Scales
(GMDS) used by the group have six subscales of develop-
ment (locomotor, personal, social, speech and hearing, eye
and hand coordination, and performance and practical rea-
soning)andageneralscoreisderivedfromtheaveragesofthe
subscale scores [39]. The Peabody Picture Vocabulary Test
(PPVT) III is a test of English receptive vocabulary [40]. Fi-
nally, the Child Behaviour Checklist (CBCL) measures pa-
rentalperceptionofchildcompetencies,behaviours,andlan-
guage development [41]. The study used all three measures
at age 2.5−3 yrs and found that the infants of the supple-
mented group had signiﬁcantly higher scores on the eye and
hand coordination subtest of the GMDS than those of the
control group (P = 0.02). However, there were no signiﬁcant
diﬀerences in the scores for any other sections of the GMDS,
the PPVT-III, or the CBCL. The relatively high doses of ω-3
PUFAsupplementationinthisstudywerenotassociatedwith
any deleterious eﬀects on neurodevelopment or growth [19].
4. Discussion
The 8 randomized trials reviewed by us focusing on the ef-
fects of maternal PUFA supplementation on the neurocog-
nitive and retinal development in the child have found very
limited, if any, beneﬁts to supplementation. Even in the stud-
ies that found statistically signiﬁcant diﬀerences between
treatment and control groups, the diﬀerences were small and
of little potential clinical importance. These trials have found
that even high doses of supplementation of ω-3 PUFA (up to
3.7g/d)werenotassociatedwithanydetrimentaleﬀects[19].
These studies did not detect a relationship between the
d o s e so fs u p p l e m e n t a t i o na n dm e a s u r e de ﬀects [18, 19]a n d
found that, although there was an association between infant
DHA status and retinal/VEP maturity, there was no correla-
tionbetweenmaternalsupplementationofPUFAsandinfant
DHA status [18, 19]. In contrast, Dunstan et al., using the
highest doses of 4×1g ﬁsh oil/day (3.7g DHA/d), found im-
proved scores only in the hand and eye coordination subtest
in the K-ABC for infants in the treatment group [19]. Al-
though the study by Judge and colleagues was well designed,
thesamplesizewassmallandthevehicleofDHAadministra-
tion (DHA-rich cereal bars) diﬀered from the other studies
on visual development which used ﬁsh oil capsules.
Measurements of maternal or infant DHA status were
not reported. The study did not report whether acuity was
tested monocularly or binocularly. As eﬀects were found atObstetrics and Gynecology International 7
4 months but not 6 months, it is possible that maternal sup-
plementation provides an initial advantage which disappears
with time. One would only expect a continued diﬀerence if
prenatal supplementation predisposed infants to have better
vision.Twodiﬀerent and inconsistent values for visual acuity
scores were presented in the abstract versus the text. Contact
with the authors clariﬁed that the value in the abstract was
based on using the GLM model (a statistical method of using
least squares to ﬁt general linear models), whereas the value
in the text was calculated using group means.
The detected diﬀerence of 0.5 cycles/degree (c/d) (see
Table 1), although statistically signiﬁcant, falls within the
normal range for age (binocular acuity) at four months (6.8–
1.7c/d)andsixmonths(9.1–2.2c/d)[25].Theauthorsnoted
that a limitation of this study was in the use of ACP, which,
although shown to be repeatable [30, 31], has inherent
subjectivity.
As in the ERG study by Malcolm [17], maternal supple-
mentation did not correlate with infant DHA status [17].
This is interesting especially because the mothers in each
group did have signiﬁcantly diﬀerent levels of DHA and
%TFA at delivery. This study used solid methodology to test
VEP responses, with the authors conducting both ﬂash and
transient pattern-reversal VEPs. The ﬂash VEP is only able
to give an indication of whether the visual cortex responds
to light stimulation, whereas the pattern-reversal VEP yields
information on the quality of the response. This may explain
why signiﬁcant diﬀerences were found in pattern-reversal
VEPs and not in ﬂash VEPs. Sweep VEPs are likely the best
wayto test corticalresponses in infants, becausetheytakethe
shortest time to elicit and there would be less chance of a
child loosing attention to the stimulus [42–44]. The authors
reported VEP results using latencies which are less variable
than amplitudes [44]. The authors of this study reported av-
eraging their trials over 30–50 epochs, which is certainly suf-
ﬁcient to minimize the signal-to-noise ratio.
The results of both studies conducted by Malcolm et al.
suggestthatinfantDHAstatus,butnotmaternalsupplemen-
tation, is correlated with infant visual development. Synthe-
sizing these three studies, at the present time a recom-
mendation to change practice and supplement all expecting
motherswithPUFAtoimproveoﬀspringvisionis supported
by the existing evidence.
The data of the studies included in this systematic re-
view could not be combined into a formal meta-analysis be-
cause the measures used in the studies varied greatly with
regard to dosage, length of supplementation, age of testing,
and the measures of eﬀect. Even without quantitatively com-
bining the results, it is evident that any beneﬁcial eﬀect from
ω-3 PUFA supplementation, if it exists, is very small and
therefore likely not clinically signiﬁcant. Cohen et al. con-
ducted an analysis on prenatal intake of n-3 PUFAs and cog-
nitive development, in which they estimated that increasing
maternalDHAintakeby1g/dmayincreasechildIQbyabout
1.3 points.
In explaining the results of the neurocognitive interven-
tions, Helland and colleagues suggested that the lack of mea-
sured eﬀect may be because the eﬀects of the ω-3 PUFAs are
dilutedbyseveralotherfactorssuchasothernutrients,drugs,
social stimulation, and diseases. Other possible explanations
were lack of eﬀect of ω-3 PUFAs or that their methods of
cognitive testing were not suﬃciently sensitive to detect dif-
ferences at these ages. Alternately, performance on the spe-
ciﬁc visual task used in the Fagan test was not impacted [20],
as found in the Judge et al. study [16]. In contrast, early neu-
rodevelopment, when assessed with a measure inclusive of
a broader range of skills (K-ABC), was sensitive to these
changes. Even when group diﬀerences in mental processing
scores were detected at four years of age, these were not of a
magnitude to make a signiﬁcant clinical impact (4 IQ points,
or about one-quarter of a standard deviation).
In synthesizing the existing neurocognitive studies, the
papers included in this systematic review have yielded varia-
ble results in terms of whether PUFA supplementation dur-
ing pregnancy was of beneﬁt to infant neurocognitive devel-
opment. In the longitudinal study by Helland et al., the lim-
ited eﬀects evident at four years of age were nulliﬁed three
years later [20–22]. In Dunstan et al.’s study, a single positive
eﬀect was contrasted by mostly negative results [19]. When
comparing numerous endpoints, a single positive result may
arise by chance only, as P<0.0 5m e a n sa1i n2 0c h a n c eo f
“no diﬀerence” becoming “signiﬁcant,” especially since mul-
tiple comparison correction for the large number of com-
parisons was not performed in Dunstan et al.’s study [19].
Similarly,Judgeetal.foundonesigniﬁcantlypositiveeﬀectin
a large number of negative tests [16]. If there was a genuine
favorable eﬀect, it was of small magnitude and may not per-
sist in later years [21]. Thus, in considering the results of
these six studies, at the present time a recommendation to
change practice and supplement all expecting mothers with
PUFA to improve infant neurodevelopment is not strongly
supported by the existing research results.
Several limitations exist in the body of knowledge ana-
lyzed by us. First, studies that examined the eﬀects of LC-
PUFAs in preterm infants were not included in this review.
However, developmental beneﬁt to PUFA supplementation
may be more consistent in infants born prematurely. It may
bearguedthataspreterminfantsaredeniedthefullgestation
periodtoaccumulateanadequateamountofDHA,theymay
beneﬁt the most from increased maternal DHA levels during
pregnancy, achieved with DHA supplementation.
Preterm infants fed with DHA-supplemented formula
have shown better visual resolution acuity at 2 and 4 months
[45] and higher Bayley mental and psychomotor develop-
ment scores at 118 weeks [46].
Second, the included studies have employed a variety of
tests in order to measure neurocognitive and retinal develop-
ment. Becausethesemeasuresassessdiﬀerent components of
brain development and aspects of cognition, it may not be
surprising that there are inconsistent results among diﬀerent
studies.
5. Conclusions
Our systematic review of RCTs suggests that the research
available to date regarding the maternal supplementation
of PUFAs in retinal and neurocognitive development of8 Obstetrics and Gynecology International
the infant is not consistent in showing a beneﬁt to supple-
mentation. However, there is evidence that dietary deﬁciency
in LC-PUFAs can adversely aﬀect retinal and neurocognitive
development outcomes in animals, and these data are cor-
roborated in nutritionally impaired women in Bangladesh
thus, it is important to maintain a healthy diet that contains
suﬃcient sources of PUFAs, such as eggs and ﬁsh.
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